Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04322552
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of SHR0410 in Hemodialysis Patients With Pruritus
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04317209
- Locations
- 🇨🇳
The first affiliated hospital of sun yat-sen university, Guangzhou, China
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-03-20
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 537
- Registration Number
- NCT04316364
- Locations
- 🇨🇳
ZheJiang Cancer Hospital, Hangzhou, Zhejiang, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Drug-drug Interaction Trial of Loperamide Pharmacokinetics Effect on Pyrotinib Maleate
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04315116
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04315493
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
- First Posted Date
- 2020-03-12
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04305392
- Locations
- 🇨🇳
Meixia Wang, Beijing, Beijing, China
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT04300114
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 474
- Registration Number
- NCT04296370
- Locations
- 🇨🇳
Jiangsu HengRui Medicine Co., Ltd., Shanghai, China
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04293029
- Locations
- 🇨🇳
The First Affiliated Hospital of Jilin University, Changchun, Jilin, China
A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-07-27
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04291846
- Locations
- 🇨🇳
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical College, Nanjing, Jiangsu, China